BurundiTuberculosis profile
Population  2016 11 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2 (1.2–3.1) 19 (12–29)
Mortality (HIV+TB only) 0.52 (0.33–0.75) 4.9 (3.1–7.1)
Incidence  (includes HIV+TB) 12 (8–18) 118 (76–169)
Incidence (HIV+TB only) 1.5 (0.96–2.2) 14 (9.1–20)
Incidence (MDR/RR-TB)** 0.42 (0.27–0.58) 4 (2.5–5.5)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.66 (0.4–0.91) 4.2 (2.5–5.8) 4.8 (2.9–6.7)
Males 0.75 (0.46–1) 6.8 (4.2–9.5) 7.6 (4.6–11)
Total 1.4 (0.86–2) 11 (6.7–15) 12 (8–18)
TB case notifications, 2016  
Total cases notified 7 662
Total new and relapse 7 567
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 96%
          - % pulmonary 73%
          - % bacteriologically confirmed among pulmonary 83%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 61% (43–94)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.21 (0.11–0.33)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 877 12%
          - on antiretroviral therapy 795 91%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  200
(160–230)
Estimated % of TB cases with MDR/RR-TB 2.8% (2.1–3.4) 13% (8.9–17)  
% notified tested for rifampicin resistance 5% 64% 615
MDR/RR-TB cases tested for resistance to second-line drugs   52
Laboratory-confirmed cases MDR/RR-TB: 80, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 80, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 92% 6 892
Previously treated cases, excluding relapse, registered in 2015 83% 77
HIV-positive TB cases registered in 2015 87% 907
MDR/RR-TB cases started on second-line treatment in 2014 90% 41
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
33% (31–37)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-17 Data: www.who.int/tb/data